ISSAQUAH, Wash., March 05, 2026 (GLOBE NEWSWIRE) — Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the second quarter (twelve weeks) and the first 24 weeks of fiscal 2026, ended February 15, 2026. Net sales for the quarter increased 9.1 percent, to $68.24 billion, from $62.53 billion last year. Net sales for the first 24 weeks increased 8.7 percent, to $134.22 billion, from $123.52 billion last year. Comparable sales for the second quarter and first 24 weeks of fiscal 2026 were as follows:    12 Weeks   12 Weeks   24 Weeks   24 Weeks          Adjusted*       Adjusted*    U.S. 5.9%   6.4%   5.9%   6.1%    Canada 10.1%   7.6%   8.3%   8.3%    Other International 13.0%   7.1%   11.0%   7.0%                       Total Company 7.4%   6.7%   6.9%   6.5%                       Digitally-Enabled 22.6%   21.7%   21.6%   21.2%  *Excluding...

SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) — CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026.First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year’s first quarter. First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year’s first quarter. First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year’s first quarter. See “Reconciliation of Selected GAAP Results to Non-GAAP Results” below.“We’re pleased to report a strong start to the fiscal year, highlighted by product launches, outstanding profitability, and robust cash flow, all of which gives us the confidence to raise both...

OAKLAND, Calif., March 05, 2026 (GLOBE NEWSWIRE) — ContextLogic Holdings Inc. (OTCQB: LOGC) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2025. Company Update Subsequent to the end of the fourth quarter 2025, the Company completed the acquisition of US Salt Parent Holdings, LLC and its subsidiaries (together, “US Salt”), marking a pivotal milestone in ContextLogic’s evolution into a business ownership platform. The Company remains focused on identifying and pursuing additional acquisitions of businesses that are niche, competitively advantaged, and built for long-duration value creation. Fourth-Quarter Fiscal 2025 Financial HighlightsOn December 8, 2025, ContextLogic announced the planned $907.5 million acquisition...

~ Surpasses $100 Million in Annual Revenue, First Time in the Company’s History ~ ~ MAUs of 52 Million in Q4, Representing 11% Quarterly Sequential Growth ~ ~ Recently Launched Rumble Shorts Tops 1 Million Daily Unique Video Views ~ ~ On Track to Complete Transformative Acquisition of AI Infrastructure Company, Northern Data, in the Second Quarter of 2026 ~ ~ Northern Data’s GPU Utilization is Expected to Approximate 85% by End of Q1 20261 ~ LONGBOAT KEY, Fla., March 05, 2026 (GLOBE NEWSWIRE) — Rumble Inc. (Nasdaq: RUM), the Freedom-First technology platform, today announced financial results for the fiscal quarter and full year ended December 31, 2025. Q4 2025 Key Highlights and Key ItemsRevenue for the fourth quarter was $27.1 million, a sequential increase of 9% from $24.8 million in the third quarter of 2025. Average global...

TORONTO, March 05, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the fourth quarter and full year ended December 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).   Business HighlightsQ4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million.Profound’s TULSA-PRO® qualified sales pipeline also continues to grow, and currently stands at 110 new systems being classified within one of the “Verify, Negotiate and Contracting” stages. The...

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520’s differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in PDAC as a panKRAS inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c restriction — establishing the clinical foundation for differentiated combination strategies, including BBOT’s internal KRAS plus PI3Kα breaker program. Clinical readouts expected in the second half of 2026 across all three programs, positioning BBOT for a...

Fourth Quarter 2025 HighlightsRevenue of $90.9 million versus $94.7 million in the prior year period GAAP net income of $5.4 million versus GAAP net income of $2.7 million in the prior year period Adjusted net income1 of $7.5 million versus adjusted net income of $4.8 million in the prior year period Adjusted EBITDA1 of $15.2 million versus Adjusted EBITDA of $13.0 million in the prior year period Flight equipment sales consisted of four engines compared to six engines in the prior year period Feedstock acquisitions of $15.4 million in the quarter2025 Full Year HighlightsRevenue of $335.3 million versus $345.1 million GAAP net income of $8.6 million versus GAAP Net Income of $5.9 million Adjusted net income1 of $15.8 million versus adjusted net income of $9.5 million Adjusted EBITDA1 of $46.1 million versus Adjusted EBITDA of $33.4...

BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights. “2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this program is delivering on the promise of an off-the-shelf CAR-T cell therapy with speed, scalability, and access. We continue to engage with the FDA on the pivotal trial design...

Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026 Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company’s strategic evolution $160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) — Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the full year ended December...

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care Expanded Antiviral Pipeline with New Hepatitis E Virus (HEV) Program; Lead Product Candidate AT-587 Expected to Enter Clinic Mid-2026 Company Holding Conference Call Today at 4:30 PM ET BOSTON, March 05, 2026 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc....